Fractyl Health Q1 net loss $3.3M; cash $121.4M; Remain-1 pivotal study H2 2024

FRACTYL HEALTH, INC.

2024-Q1 EPS reported -$0.17 revenue$33,000

Net loss $3.3M vs $11.9M YoY; includes $17.1M non-cash gain from fair value changes.
Cash and cash equivalents $121.4M as of March 31, 2024; expected to fund operations through 2025.
Expects to initiate Remain-1 pivotal study for weight maintenance after GLP-1 discontinuation in H2 2024.
Topline data from Revitalize-1 pivotal T2D study anticipated in Q4 2024; enrollment completion expected Q2 2024.
Appointed Adrian Kimber as Chief Commercial Officer; Germany registry study shows HbA1c reduction >1% and weight loss >15 lbs at 3 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FRACTYL HEALTH, INC. reported first quarter 2024 results: revenue Revenue in the quarter ended March 31, 2024.

Period: first quarter 2024
Revenue: Revenue in the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today reported its first quarter 2024 financial results

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

FRACTYL HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-058615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.